Orciprenaline, also known as metaproterenol, is a bronchodilator used in the treatment of asthma. Orciprenaline is a moderately selective β2 adrenergic receptor agonist that stimulates receptors of the smooth muscle in the lungs, uterus, and vasculature s + some more technical info It is typically supplied as the sulfate salt to enhance stability and aqueous solubility and is formulated for inhalation, nebulization or oral delivery depending on product design. At the cellular level orciprenaline activates Gs-coupled β2 receptors, increasing intracellular cyclic AMP and causing relaxation of bronchial smooth muscle; clinical selectivity for β2 over β1 receptors reduces but does not eliminate cardiac effects, so tachycardia, palpitations and tremor are recognized dose-related adverse effects. Metabolism involves hepatic conjugation and catechol-O-methyltransferase mediated O-methylation with renal excretion of metabolites, and routine quality control uses validated HPLC and mass spectrometry methods to confirm potency, purity and stability.
Parent: Orciprenaline
Parent: Orciprenaline
Parent: Orciprenaline
Parent: Orciprenaline Sulfate / Orciprenaline
Known related substances and degradation products for orciprenaline include positional isomers of the catechol ring, N-dealkylation products, mono- and di-oxidized species such as quinone-type oxidation products, and salt/form-related variants (sulfate versus free base); manufacturing process impurities can include residual solvents and reagents. Typical specification practices applied by manufacturers set individual unspecified impurity limits in the range of 0.1% to 0.3% and a total related substances limit around 1.0%, while identified or toxicologically relevant impurities are often controlled to tighter levels (for example 0.05% to 0.1%). Identification and quantification are performed by stress testing followed by HPLC-UV with MS confirmation, with batch release criteria such as assay 98% to 102% of label claim and compliance with ICH limits for residual solvents and elemental impurities.
Orciprenaline is used primarily for relief and prevention of bronchospasm in asthma and other reversible obstructive airway diseases; it can be delivered by inhalation, nebulizer or oral formulation depending on the product.
Yes, orciprenaline can increase heart rate; although it is relatively β2 selective, higher doses or systemic exposure can produce β1 mediated cardiac stimulation and reflex tachycardia, so heart rate should be monitored in susceptible patients.
Orcibest is a brand formulation of orciprenaline and belongs to the bronchodilator class of drugs, specifically the β2-adrenergic receptor agonists.
Data are limited; orciprenaline and its metabolites may be excreted in breast milk, so use during lactation should be based on a risk-benefit assessment and under medical advice, with consideration of alternative agents with more established safety data for breastfeeding mothers.
